Cargando…

The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus

A hallmark of systemic lupus erythematosus (SLE) is the appearance of autoantibodies to nuclear antigens, including autoantibodies directed to the heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2), which occur in 20% to 30% of SLE patients as well as in animal models of this disease. To investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Fritsch-Stork, Ruth, Müllegger, Daniela, Skriner, Karl, Jahn-Schmid, Beatrice, Smolen, Josef S, Steiner, Günter
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779394/
https://www.ncbi.nlm.nih.gov/pubmed/16859514
http://dx.doi.org/10.1186/ar2007
_version_ 1782131759039643648
author Fritsch-Stork, Ruth
Müllegger, Daniela
Skriner, Karl
Jahn-Schmid, Beatrice
Smolen, Josef S
Steiner, Günter
author_facet Fritsch-Stork, Ruth
Müllegger, Daniela
Skriner, Karl
Jahn-Schmid, Beatrice
Smolen, Josef S
Steiner, Günter
author_sort Fritsch-Stork, Ruth
collection PubMed
description A hallmark of systemic lupus erythematosus (SLE) is the appearance of autoantibodies to nuclear antigens, including autoantibodies directed to the heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2), which occur in 20% to 30% of SLE patients as well as in animal models of this disease. To investigate the underlying cellular reactivity and to gain further insight into the nature and potential pathogenic role of this autoimmune response we characterized the T cell reactivity against hnRNP-A2 in patients with SLE in comparison to healthy controls. Cellular proliferation of peripheral blood T cells to hnRNP-A2 was determined by [3H]thymidine incorporation and T cell clones (TCCs) specific for hnRNP-A2 were grown by limiting dilution cloning; IFNγ, IL-4 and IL-10 in culture supernatants were measured by ELISA. Bioactivity of culture supernatants was determined by incubation of anti-CD3/anti-CD28 stimulated peripheral blood CD4+ T cells with supernatants of TCCs. Stimulation assays performed with peripheral blood mononuclear cells of 35 SLE patients and 21 healthy controls revealed pronounced proliferative responses in 66% of SLE patients and in 24% of the controls, which were significantly higher in SLE patients (p < 0.00002). Furthermore, hnRNP-A2 specific TCCs generated from SLE patients (n = 22) contained a relatively high proportion of CD8+ clones and mostly lacked CD28 expression, in contrast to TCCs derived from healthy controls (n = 12). All CD4+ TCCs of patients and all control TCCs secreted IFNγ and no IL-4. In contrast, CD8+ TCCs of patients secreted very little IFNγ, while production of IL-10 did not significantly differ from other T cell subsets. Interestingly, all CD8+ clones producing IL-10 in large excess over IFNγ lacked expression of CD28. Functional assays showed a stimulatory effect of the supernatants derived from these CD8+CD28- hnRNP-A2 specific TCCs that was similar to that of CD4+CD28+ clones. Taken together, the pronounced peripheral T cell reactivity to hnRNP-A2 observed in the majority of SLE patients and the distinct phenotype of patient-derived CD8+ TCCs suggest a role for these T cells in the pathogenesis of SLE.
format Text
id pubmed-1779394
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-17793942007-01-19 The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus Fritsch-Stork, Ruth Müllegger, Daniela Skriner, Karl Jahn-Schmid, Beatrice Smolen, Josef S Steiner, Günter Arthritis Res Ther Research Article A hallmark of systemic lupus erythematosus (SLE) is the appearance of autoantibodies to nuclear antigens, including autoantibodies directed to the heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2), which occur in 20% to 30% of SLE patients as well as in animal models of this disease. To investigate the underlying cellular reactivity and to gain further insight into the nature and potential pathogenic role of this autoimmune response we characterized the T cell reactivity against hnRNP-A2 in patients with SLE in comparison to healthy controls. Cellular proliferation of peripheral blood T cells to hnRNP-A2 was determined by [3H]thymidine incorporation and T cell clones (TCCs) specific for hnRNP-A2 were grown by limiting dilution cloning; IFNγ, IL-4 and IL-10 in culture supernatants were measured by ELISA. Bioactivity of culture supernatants was determined by incubation of anti-CD3/anti-CD28 stimulated peripheral blood CD4+ T cells with supernatants of TCCs. Stimulation assays performed with peripheral blood mononuclear cells of 35 SLE patients and 21 healthy controls revealed pronounced proliferative responses in 66% of SLE patients and in 24% of the controls, which were significantly higher in SLE patients (p < 0.00002). Furthermore, hnRNP-A2 specific TCCs generated from SLE patients (n = 22) contained a relatively high proportion of CD8+ clones and mostly lacked CD28 expression, in contrast to TCCs derived from healthy controls (n = 12). All CD4+ TCCs of patients and all control TCCs secreted IFNγ and no IL-4. In contrast, CD8+ TCCs of patients secreted very little IFNγ, while production of IL-10 did not significantly differ from other T cell subsets. Interestingly, all CD8+ clones producing IL-10 in large excess over IFNγ lacked expression of CD28. Functional assays showed a stimulatory effect of the supernatants derived from these CD8+CD28- hnRNP-A2 specific TCCs that was similar to that of CD4+CD28+ clones. Taken together, the pronounced peripheral T cell reactivity to hnRNP-A2 observed in the majority of SLE patients and the distinct phenotype of patient-derived CD8+ TCCs suggest a role for these T cells in the pathogenesis of SLE. BioMed Central 2006 2006-07-19 /pmc/articles/PMC1779394/ /pubmed/16859514 http://dx.doi.org/10.1186/ar2007 Text en Copyright © 2006 Fritsch-Stork et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fritsch-Stork, Ruth
Müllegger, Daniela
Skriner, Karl
Jahn-Schmid, Beatrice
Smolen, Josef S
Steiner, Günter
The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
title The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
title_full The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
title_fullStr The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
title_full_unstemmed The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
title_short The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
title_sort spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein a2 (hnrnp-a2) is a major t cell autoantigen in patients with systemic lupus erythematosus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779394/
https://www.ncbi.nlm.nih.gov/pubmed/16859514
http://dx.doi.org/10.1186/ar2007
work_keys_str_mv AT fritschstorkruth thespliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT mulleggerdaniela thespliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT skrinerkarl thespliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT jahnschmidbeatrice thespliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT smolenjosefs thespliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT steinergunter thespliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT fritschstorkruth spliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT mulleggerdaniela spliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT skrinerkarl spliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT jahnschmidbeatrice spliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT smolenjosefs spliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus
AT steinergunter spliceosomalautoantigenheterogeneousnuclearribonucleoproteina2hnrnpa2isamajortcellautoantigeninpatientswithsystemiclupuserythematosus